Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)

Annales d'Endocrinologie

Volumn 69, Issue 2, 2008, Pages 162-163

  Schmid, H A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CORTICOTROPIN; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; GROWTH HORMONE; HYDROCORTISONE; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SOMATOMEDIN C; VASCULOTROPIN;

ACROMEGALY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; ENDOCRINE DISEASE; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; NONHUMAN; RECEPTOR AFFINITY; TACHYPHYLAXIS;

ANIMALS; ENDOCRINE SYSTEM DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OLIGOPEPTIDES; PROTEIN KINASES; RECEPTORS, SOMATOSTATIN; SIROLIMUS;

EID: 42749095844     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2008.02.020     Document Type: Article

References (15)

1. Bruns C., Lewis I., Briner U., Meno-Tetang G., and Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad Somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146 (2002) 707-716
2. Farrrall A.J., Glusman J.E., Buchelt A., Gao B., and Petersenn S. Pasireotide (SOM230) effectively reduces pituitary tumor volume with active acromegaly: results from Phase II trial. ENDO (2007) OR53-OR54
3. Hofland L.J., VanDerHoek J., Feelders R., van Aken M.O., vanKoetsveld P.M., Waaijers M., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152 (2005) 645-654
4. Musat M., Korbonits M., Kola B., Borboli N., Hanson M.R., Nanzer A.M., et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 12 (2005) 423-433
5. O'Reilly K.E., Rojo F., She Q.-B., Solit D., Mills G.B., Smith D., et al. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Res 66 3 (2006) 1500-1508
6. Schmid H.A., and Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (2004) 47-50
7. Schmid H.A., and Silva A.P. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest 28 (2005) 28-35
8. Schmid HA. (2008). Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol (in press).
9. Silva A.P., Schoeffter P., Weckbecker G., Bruns C., and Schmid H.A. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153 (2005) R7-R10
10. Theodoropoulou M., Zhang J., Laupheimer S., Paez-Pereda M., Erneux C., Florio T., et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66 3 (2006) 1576-1582
11. VanDerHoek J., deHerder W.W., Feelders R.A., vanderLely A.J., Uitterlinden P., Boerlin V., et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89 (2004) 638-645
12. Van Der Hoek J., Waaijers M., van Koetsveld P.M., Sprij-Mooij D., Feelders R.A., Schmid H.A., et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. Am J Physiol Endocrinol Metab 289 (2005) E278-E287
13. von Wichert G., Haeussler U., Greten F.R., Kliche S., Dralle H., Böhm B.O., et al. Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 24 (2005) 1284-1289
14. Yao J.C. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21 1 (2007) 163-172
15. Zitzmann K., De Toni E.N., Brand S., Goke B., Meinecke J., Spottl G., et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 1 (2007) 54-60